Abstract
Among men with clinically low-risk prostate cancer, we have previously documented heterogeneity in terms of clinical characteristics and genomic risk scores. To further study the underlying tumor biology of this patient population, by interrogating broader patterns of gene expression among men with clinically low-risk tumors. Prostate biopsies from 427 patients considered potentially suitable for active surveillance underwent central pathology review and genome-wide expression profiling. These cases were compared with 1290 higher-risk biopsy cases with diverse clinical features from a prospective genomic registry. Average genomic risk (AGR) was determined from 18 published prognostic signatures, and MSigDB hallmark gene sets were analyzed using bootstrapped clustering methods. These sets were examined in relation to clinical variables and pathological and biochemical outcomes using multivariable regression analysis. A total of 408 (96%) biopsies passed RNA quality control. Based on AGR quartiles defined by the high-risk multicenter cases, the University of California, San Francisco (UCSF) low-risk patients were distributed across the quartiles as 219 (54%), 107 (26%), 61 (15%), and 21 (5%). Unsupervised clustering analysis of t...Continue Reading
Citations
Dec 19, 2018·JAMA : the Journal of the American Medical Association·Brandon A MahalFranklin W Huang
Aug 29, 2019·Prostate Cancer and Prostatic Diseases·Annika HerlemannMatthew R Cooperberg
Dec 13, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Scott E EggenerHimisha Beltran
Sep 5, 2020·Expert Review of Molecular Diagnostics·Fernando López-CamposFelipe Couñago
Aug 2, 2019·Medicines·Ugo TestaElvira Pelosi
Jul 28, 2019·Medicine·Hai-Ming CaoChao Guan
Oct 23, 2019·International Journal of Oncology·Xiaozeng LinDamu Tang
Aug 28, 2020·JAMA Oncology·Matthew R CooperbergDaniel W Lin
Sep 10, 2019·Expert Review of Molecular Diagnostics·Philip ZeuschnerKerstin Junker
Apr 2, 2020·Prostate Cancer and Prostatic Diseases·Jeffrey J TosoianDaniel E Spratt
Dec 20, 2018·Histopathology·Yuri Tolkach, Glen Kristiansen
Mar 9, 2019·European Radiology·Andrei S PuryskoEric A Klein
May 21, 2020·Cancers·Yuqian GaoTao Liu
Aug 12, 2018·Nature Reviews. Urology·Vidit Sharma, R Jeffrey Karnes
Jul 30, 2020·Scientific Reports·Johannes LinxweilerMatthias Saar
Oct 10, 2020·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Kelly HewittLaura J Esserman
Nov 6, 2020·European Urology·Matthew R CooperbergPamela L Paris
Jul 6, 2020·European Urology·Marco BorghesiCarlo Terrone
Dec 17, 2019·Clinical Oncology : a Journal of the Royal College of Radiologists·R T Dess, D E Spratt
Jan 13, 2021·World Journal of Urology·Craig V LabbateScott E Eggener
Mar 4, 2021·World Journal of Urology·Colton H WalkerTodd M Morgan
May 29, 2020·European Urology·Amar U KishanJoanne B Weidhaas
Apr 10, 2021·Nature Reviews. Urology·Sean F MungovanManish I Patel
Jun 5, 2021·Communications Biology·Walter RayfordAshutosh K Tewari
Jul 22, 2021·Prostate Cancer and Prostatic Diseases·Randy A VinceTodd M Morgan
Jan 28, 2022·World Journal of Urology·Alexander KretschmerMikkel Noerholm